Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study

To evaluate the utility of transcript profiling for prediction of protein expression levels, we compared profiles across the NCI-60 cancer cell panel, which represents nine tissues of origin. For that analysis, we present here two new NCI-60 transcript profile data sets (A based on Affymetrix HG-U95 and HG-U133A chips; Affymetrix, Santa Clara, CA) and one new protein profile data set (based on reverse-phase protein lysate arrays). The data sets are available online at http://discover.nci.nih.gov in the CellMiner program package. Using the new transcript data in combination with our previously published cDNA array and Affymetrix HU6800 data sets, we first developed a “consensus set” of transcript profiles based on the four different microarray platforms. Using that set, we found that 65% of the genes showed statistically significant transcript-protein correlation, and the correlations were generally higher than those reported previously for panels of mammalian cells. Using the predictive analysis of microarray nearest shrunken centroid algorithm for functional prediction of tissue of origin, we then found that (a) the consensus mRNA set did better than did data from any of the individual mRNA platforms and (b) the protein data seemed to do somewhat better (P = 0.027) on a gene-for-gene basis in this particular study than did the consensus mRNA data, but both did well. Analysis based on the Gene Ontology showed protein levels of structure-related genes to be well predicted by mRNA levels (mean r = 0.71). Because the transcript-based technologies are more mature and are currently able to assess larger numbers of genes at one time, they continue to be useful, even when the ultimate aim is information about proteins. [Mol Cancer Ther 2007;6(3):820–32]

[1]  John N Weinstein,et al.  Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. , 2004, Cancer cell.

[2]  G. S. Johnson,et al.  An Information-Intensive Approach to the Molecular Pharmacology of Cancer , 1997, Science.

[3]  J N Weinstein,et al.  A protein expression database for the molecular pharmacology of cancer , 1997, Electrophoresis.

[4]  D. Botstein,et al.  A gene expression database for the molecular pharmacology of cancer , 2000, Nature Genetics.

[5]  John N Weinstein,et al.  Analysis of ATP-Binding Cassette Transporter Expression in Drug-Selected Cell Lines by a Microarray Dedicated to Multidrug Resistances⃞ , 2004, Molecular Pharmacology.

[6]  D A Scudiero,et al.  Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. , 1989, Journal of the National Cancer Institute.

[7]  Fuad G. Gwadry,et al.  Comparing cDNA and oligonucleotide array data: concordance of gene expression across platforms for the NCI-60 cancer cells , 2003, Genome Biology.

[8]  J N Weinstein,et al.  Neural computing in cancer drug development: predicting mechanism of action. , 1992, Science.

[9]  R. Tibshirani,et al.  Diagnosis of multiple cancer types by shrunken centroids of gene expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[10]  E. Petricoin,et al.  Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front , 2001, Oncogene.

[11]  A. Bretscher,et al.  Fimbrin, a new microfilament-associated protein present in microvilli and other cell surface structures , 1980, The Journal of cell biology.

[12]  Donna R. Maglott,et al.  RefSeq and LocusLink: NCBI gene-centered resources , 2001, Nucleic Acids Res..

[13]  G. Perozzi,et al.  Transcriptional regulation of the ezrin gene during rat intestinal development and epithelial differentiation. , 1995, Biochimica et biophysica acta.

[14]  T. Ørntoft,et al.  Gene expression profiling: monitoring transcription and translation products using DNA microarrays and proteomics , 2000, FEBS letters.

[15]  J. Seilhamer,et al.  A comparison of selected mRNA and protein abundances in human liver , 1997, Electrophoresis.

[16]  H. Furthmayr,et al.  Moesin: a member of the protein 4.1-talin-ezrin family of proteins. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[17]  William C Reinhold,et al.  Transcriptional regulation of mitotic genes by camptothecin-induced DNA damage: microarray analysis of dose- and time-dependent effects. , 2002, Cancer research.

[18]  J. Mesirov,et al.  Chemosensitivity prediction by transcriptional profiling , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[19]  William C Reinhold,et al.  Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel , 2006, Molecular Cancer Therapeutics.

[20]  M R Grever,et al.  The National Cancer Institute: cancer drug discovery and development program. , 1992, Seminars in oncology.

[21]  M. Chavance.  [Jackknife and bootstrap]. , 1992, Revue d'epidemiologie et de sante publique.

[22]  William C Reinhold,et al.  Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[23]  S. Holbeck,et al.  Update on NCI in vitro drug screen utilities. , 2004, European journal of cancer.

[24]  M. Boyd,et al.  Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen , 1995 .

[25]  Christian A. Rees,et al.  Systematic variation in gene expression patterns in human cancer cell lines , 2000, Nature Genetics.

[26]  S. Gygi,et al.  Quantitative analysis of complex protein mixtures using isotope-coded affinity tags , 1999, Nature Biotechnology.

[27]  Sharon L R Kardia,et al.  Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  V. Thorsson,et al.  Integrated Genomic and Proteomic Analyses of Gene Expression in Mammalian Cells*S , 2004, Molecular & Cellular Proteomics.

[29]  John N Weinstein,et al.  Integromic analysis of the NCI-60 cancer cell lines. , 2004, Breast disease.

[30]  John N. Weinstein,et al.  Spotlight on molecular profiling: “Integromic” analysis of the NCI-60 cancer cell lines , 2006, Molecular Cancer Therapeutics.

[31]  M. Boyd,et al.  Morphological and immunocytochemical characteristics of human tumor cell lines for use in a disease-oriented anticancer drug screen. , 1992, Anticancer research.

[32]  R. Young,et al.  Biomedical Discovery with DNA Arrays , 2000, Cell.

[33]  D. Scudiero,et al.  Development of human tumor cell line panels for use in disease-oriented drug screening. , 1988, Progress in clinical and biological research.

[34]  T. Tatusova,et al.  Entrez Gene: gene-centered information at NCBI , 2006, Nucleic Acids Res..

[35]  D. Scudiero,et al.  Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. , 1991, Journal of the National Cancer Institute.

[36]  David E. Misek,et al.  Discordant Protein and mRNA Expression in Lung Adenocarcinomas * , 2002, Molecular & Cellular Proteomics.

[37]  A. Quaroni,et al.  Differential localization by in situ hybridization of distinct keratin mRNA species during intestinal epithelial cell development and differentiation. , 1993, Differentiation; research in biological diversity.

[38]  J. Weinstein,et al.  Transcriptomic analysis of the NCI-60 cancer cell lines. , 2003, Comptes rendus biologies.

[39]  William C Reinhold,et al.  MatchMiner: a tool for batch navigation among gene and gene product identifiers , 2003, Genome Biology.